Guidant maintained by JMP at market perform

Guidant Corp. was maintained by JMP Securities analyst Robert C. Faulkner at a market perform rating. JMP said it believes Boston Scientific Corp. is a better combination than a merger of Johnson & Johnson and Guidant based on equity for investors. Boston Scientific is riskier equity, but the risk is more than offset by the potential returns, JMP said. Shares of the Indianapolis pharmaceutical company were up 78 cents, or 1.18%, at $66.70 on volume of 2,956,000 versus the three-month running average of 6,303,160 shares.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.